Sutro Biopharma (NASDAQ:STRO – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Sutro Biopharma to post earnings of ($0.86) per share and revenue of $12.18 million for the quarter.
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($2.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($2.10). Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. The company had revenue of $14.00 million for the quarter, compared to analyst estimates of $10.44 million. During the same period in the prior year, the company earned ($1.78) EPS. On average, analysts expect Sutro Biopharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Sutro Biopharma Stock Performance
STRO opened at $0.81 on Monday. Sutro Biopharma has a 1 year low of $0.81 and a 1 year high of $6.13. The company’s 50 day simple moving average is $1.75 and its 200 day simple moving average is $2.72. The stock has a market capitalization of $66.80 million, a PE ratio of -0.50 and a beta of 1.22.
Wall Street Analysts Forecast Growth
Get Our Latest Report on Sutro Biopharma
Sutro Biopharma Company Profile
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
See Also
- Five stocks we like better than Sutro Biopharma
- Stock Sentiment Analysis: How it Works
- How to Build the Ultimate Everything ETF Portfolio
- How to Calculate Inflation Rate
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.